Research

April 15, 2021

Method proposed to correct misinterpretations of long-term survival rates for immunotherapies

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

By Tom Wilemon
April 15, 2021

New insights into kidney development

Integrin-linked kinase, a central component of a complex that coordinates cell signaling involved in migration, proliferation and cell death, plays a role in kidney development and epithelial cell function.

By Bill Snyder
April 15, 2021

Arrhythmia culprit: supertrafficking ion channel

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.

By Leigh MacMillan
Benjamin Brown, left, Jens Meiler, PhD, Zhenfang Du, PhD, and colleagues are studying the functional consequences of genetic mutations and how those changes can drive cancerous growth.
April 8, 2021

Personalized Structural Biology aids cancer treatment decisions

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

By Bill Snyder
From left, Kimryn Rathmell, MD, PhD, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell, PhD, have discovered that immune cells — not cancer cells — are the major glucose consumers in the tumor microenvironment, upending a century-old observation.
April 7, 2021

Study revises understanding of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

By Leigh MacMillan
April 6, 2021

Genetic differences in Wilms tumor

Unique somatic gene mutations may contribute to racial disparities in the incidence of Wilms tumor — the most common childhood kidney cancer.

By Leigh MacMillan
April 5, 2021

Codeine metabolizer status in clinical practice

Vanderbilt researchers have developed a response score using genetic and clinical information to aid prescribing of the widely used pain medication codeine.
By Leigh MacMillan
April 1, 2021

COVID-19 met with intensive teamwork

Team members serving COVID-19 inpatients were more densely connected, interacting far more than their medical ICU counterparts.
By Paul Govern
April 1, 2021

Novel way to neutralize Rift Valley Fever Virus

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.
By Bill Snyder
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.
By Leigh MacMillan
April 1, 2021

Study shows new COVID target could improve vaccines

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.
By Bill Snyder
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
By Tom Wilemon
March 25, 2021

Team studies new use for pulmonary hypertension drug

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
By Leigh MacMillan
1 … 52 53 54 55 56 … 125